This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejectionfraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preservedejectionfraction (HFmrEF/HFpEF) and is associated with worse outcomes.
Methods Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preservedejectionfraction were enrolled from 220 centres in 41 European or ESC affiliated countries.
"We're pleased to present the RELIEVE-HF data at this year's ACC meeting, as we continue to advance this important technology with the goal of bringing a much-needed treatment option to patients with advanced heart failure, a leading cause of death and hospitalization in the U.S. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave.
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejectionfraction (HFrEF) and heart failure with preservedejectionfraction (HFpEF).
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejectionfraction (HFrEF) and heart failure with preservedejectionfraction (HFpEF).
MethodsFrom December 1, 2022 to February 1, 2024, 103 patients with heart failure were consecutively enrolled from the cardiology clinic or ward of the First Affiliated Hospital of Nanjing Medical University. Patients diagnosed with preservedejectionfraction (HFpEF) were treated with Vericiguat combined with “ARNI, BB, SGLT2i” therapy.
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preservedejectionfraction and obesity. vs. +15 KCCQ-CSS points). vs. -2.2%).
Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. The safety and tolerability of the drug in this phase 2 trial was excellent.
What better way to join the fall festivities than by spotlighting key insights in cardiorenal metabolic medicine, primary prevention, and quality of life improvements shared at this year’s biggest U.S. cardiometabolic health CME/CE conference: the 19th Annual CMHC.
BackgroundHeart failure with preservedejectionfraction (HFpEF) and atrial fibrillation (AF) often coincide. During follow-up, HFpEF-patients more often experienced AF-related re-hospitalization (36.8% Forty-two were female. ml/m2 vs. 25.8 ml/m2, g/m2 vs. 83.0 g/m2, ml/m2 vs. 25.8 ml/m2, g/m2 vs. 83.0 g/m2,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
75 
Let's personalize your content